Literature DB >> 17445931

Exercise training for patients with cardiovascular disease.

J M Casillas1, V Gremeaux, S Damak, A Feki, D Pérennou.   

Abstract

This review surveys effort training, a validated and recommended therapy, in patients with atheromatous cardiovascular disease. This true therapy reduces mortality by 25-35%, reduces clinical manifestations and complications (rhythm problems, thrombosis) and improves physical capacity, reintegration and quality of life. The effects are essentially linked to improved metabolic performance of muscles and reduced endothelial dysfunction, insulin resistance and neurohormonal abnormalities. Training also has an impact on the evolution of major risk factors, especially diabetes and arterial hypertension. The risks are limited as long as the contraindications are respected and the programmes supervised. The indications (stable angina, chronic heart failure, peripheral arterial disease) should be described more precisely by taking into account functional criteria: physical deconditioning, exclusion, compliance, mood swings, and seriousness of risk factors. The training programme should be tailor made and based on evaluation of the patient's adaptation to effort, in terms of frequency, intensity and duration of the exercises. Various types of exercise include overall or segmental physical training; concentric, eccentric, even isokinetic muscle contraction exercises; and proprioceptive rehabilitation. However, knowledge is lacking about the molecular mechanisms of the effects of training, the most effective intensity of effort, and strategies to develop physical activity in this ever-growing population for both primary and secondary prevention.

Entities:  

Mesh:

Year:  2007        PMID: 17445931     DOI: 10.1016/j.annrmp.2007.03.007

Source DB:  PubMed          Journal:  Ann Readapt Med Phys        ISSN: 0168-6054


  7 in total

Review 1.  Exercise training and peripheral arterial disease.

Authors:  Tara L Haas; Pamela G Lloyd; Hsiao-Tung Yang; Ronald L Terjung
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

2.  Leisure-time physical activity and all-cause mortality in an elderly cohort.

Authors:  Oliver Bembom; Mark van der Laan; Thaddeus Haight; Ira Tager
Journal:  Epidemiology       Date:  2009-05       Impact factor: 4.822

3.  Exercise training attenuates hypertension and cardiac hypertrophy by modulating neurotransmitters and cytokines in hypothalamic paraventricular nucleus.

Authors:  Lin-Lin Jia; Yu-Ming Kang; Fu-Xin Wang; Hong-Bao Li; Yan Zhang; Xiao-Jing Yu; Jie Qi; Yu-Ping Suo; Zhen-Jun Tian; Zhiming Zhu; Guo-Qing Zhu; Da-Nian Qin
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

4.  Exercise training attenuates renovascular hypertension partly via RAS- ROS- glutamate pathway in the hypothalamic paraventricular nucleus.

Authors:  Yan Zhang; Xiao-Jing Yu; Wen-Sheng Chen; Hong-Li Gao; Kai-Li Liu; Xiao-Lian Shi; Xiao-Yan Fan; Lin-Lin Jia; Wei Cui; Guo-Qing Zhu; Jin-Jun Liu; Yu-Ming Kang
Journal:  Sci Rep       Date:  2016-11-24       Impact factor: 4.379

5.  Physical activity, cardiovascular health, quality of life and blood pressure control in hypertensive subjects: randomized clinical trial.

Authors:  Victoria Arija; Felipe Villalobos; Roser Pedret; Angels Vinuesa; Dolors Jovani; Gabriel Pascual; Josep Basora
Journal:  Health Qual Life Outcomes       Date:  2018-09-14       Impact factor: 3.186

6.  Does CABG with Saphenous Vein Grafting and Standard Cardiac Rehabilitation Affect Lower Limb Function? A Clinical Study.

Authors:  Aleksandra Skomudek; Grzegorz Waz; Krystyna Rozek-Piechura
Journal:  Int J Environ Res Public Health       Date:  2019-05-29       Impact factor: 3.390

7.  Short-Term Water- and Land-Based Exercise Training Comparably Improve Exercise Capacity and Vascular Function in Patients After a Recent Coronary Event: A Pilot Randomized Controlled Trial.

Authors:  Danijela Vasić; Marko Novaković; Mojca Božič Mijovski; Breda Barbič Žagar; Borut Jug
Journal:  Front Physiol       Date:  2019-07-16       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.